Diet drugs strike out in weight-loss game

October 1997
Environmental Nutrition;Oct97, Vol. 20 Issue 10, p3
Discloses the plunge in prescriptions for the fen-phen weight-loss drugs after a link was established between primary pulmonary hypertension (PPH) and the use of fenfluramine. US Food and Drug Administration's (FDA) announcement that 24 women taking fen-phen had suffered heart valve deterioration; Brain damage from either fenfluramine or dexfenfluramine; Nutri/System's use of phentermine and Prozac combination or phen-pro.


Related Articles

  • Initial weight loss as a predictor of response to obesity drugs. Dhurandhar, N V; Blank, R C; Schumacher, D; Atkinson, R L // International Journal of Obesity & Related Metabolic Disorders;Dec1999, Vol. 23 Issue 12, p1333 

    BACKGROUND: Initial weight loss has been used as a predictor of long-term response to obesity drugs. Discontinuation of drugs has been recommended if weight loss is not ≥ 1.81 kg (4 Ib) in the first month of treatment. OBJECTIVE: We compared the weight loss response at 6 months of patients...

  • Tracking the `fenphen' drug trend.  // Physician & Sportsmedicine;Sep96, Vol. 24 Issue 9, p17 

    Reports on the popularity of the drugs fenfluramine and phentermine for weight reduction and appetite suppression. Mechanism by which both drugs promote weight loss; Prescription dosages of both drugs; Method by which physicians arrive at a decision to five the fenfluramine-phentermine...

  • The fen-phen summer: Weight loss brings unexpected results. Plutowski, Shelly // Communication World;Apr/May98, Vol. 15 Issue 5, p28 

    Reports on the successful effort of the Mayo Clinic's division of communication in Rochester, Minnesota to ban a weight loss drug because users are developing valvular heart disease. Presentation of facts; Challenge of communicating study results without a formal scientific publication; Use of...

  • Diet combo fen-phen again in hot water.  // Environmental Nutrition;Aug97, Vol. 20 Issue 8, p1 

    Warns against the use of the weight-loss drug combination `fen-phen' (fenfluramine plus phentermine). Link to a serious heart valve condition and primary pulmonary hypertension; Lack of conclusiveness of the link.

  • Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status. Whigham, L. D.; Dhurandhar, N. V.; Rahko, P. S.; Atkinson, R. L. // International Journal of Obesity;May2007, Vol. 31 Issue 5, p850 

    Background:Obesity treatment with single drugs produces weight losses of about 8–10% of initial body weight. Few studies of combinations of drugs for treating obesity have been published. The combination of phentermine, an adrenergic agent, and fenfluramine, a serotonergic agent,...

  • Phen-fen health risks stir pharmacy's conscience.  // Drug Store News;11/17/97, Vol. 19 Issue 19, pCP1 

    Focuses on Arizona pharmacists' reports that they are receiving undue pressure from their supervisors to continue dispensing the phentermine and fenfluramine or phen-fen combination. Personal concerns about health risks posed by the drugs.

  • Study warns of weight pill risks. Tangley, Laura; Witkin, Gordon // U.S. News & World Report;07/21/97, Vol. 123 Issue 3, p37 

    Reports that physicians have warned that a popular diet pill combination, fenfluramine and phentermine, may cause severe damage to heart valves. Number of prescriptions written for the drugs in 1996; The Food and Drug Administration's warning to physicians.

  • Fen-phen: Risky for dieters in any form.  // Consumer Reports;Sep97, Vol. 62 Issue 9, p6 

    Reports on the dangers of the diet drug fen-phen and its herbal counterpart, Herbal Fen-Phen. Where Herbal Fen-Phen is sold; Why the US Food and Drug Administration recommended against the use of fen-phen; Deaths related to the use of fen-phen.

  • Every New Mexico drugstore sued over phen-fen. Conlan, Michael F. // Drug Topics;12/7/98, Vol. 142 Issue 23, p24 

    Reports on the state lawsuit against 281 community pharmacies in New Mexico filed at the District Court in Santa Fe in 1998. Allegations of the plaintiffs regarding the manufacturers and sellers of fenfluramine-phentermine; Highlights of the case.


Read the Article

Other Topics